US 12,285,433 B2
Diltiazem for use in the treatment of microbial infections
Manuel Rosa-Calatrava, Lyons (FR); Olivier Terrier, Lyons (FR); Claire Nicolas De Lamballerie, Ensues la Redonne (FR); Guy Boivin, Quebec (CA); and Mario Andres Pizzorno, Lyons (FR)
Assigned to UNIVERSITE CLAUDE BERNARD LYON 1, Villeurbanne (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); ECOLE NORMALE SUPERIEURE DE LYON, Lyons (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and UNIVERSITE LAVAL, Quebec (CA)
Appl. No. 17/057,141
Filed by UNIVERSITE CLAUDE BERNARD LYON 1, Mlleurbanne (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); ECOLE NORMALE SUPERIEURE DE LYON, Lyons (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and UNIVERSITE LAVAL, Quebec (FR)
PCT Filed May 23, 2019, PCT No. PCT/FR2019/051186
§ 371(c)(1), (2) Date Nov. 20, 2020,
PCT Pub. No. WO2019/224489, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 1854307 (FR), filed on May 23, 2018.
Prior Publication US 2021/0154205 A1, May 27, 2021
Int. Cl. A61K 31/554 (2006.01); A61K 45/06 (2006.01); A61P 31/04 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01)
CPC A61K 31/554 (2013.01) [A61K 45/06 (2013.01); A61P 31/04 (2018.01); A61P 31/14 (2018.01); A61P 37/04 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A method for treating an infection in an individual infected with a parainfluenza virus (hPIV), comprising the administration of diltiazem to said individual, to activate the expression of at least one gene encoding a type III interferon.